Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2000

View Archived Issues

Research points to existence of a third hereditary breast cancer gene

Carbapenems display potent and broad antianaerobic activity

Scientists uncover vital role of activin A in neuroprotection after brain injury

Neurotransmitter inhibits food intake in rats

Ceramide-coated catheters significantly reduce restenosis in vivo

Orally bioavailable potassium (IKs) blockers synthesized by Bristol-Myers Squibb

More potent and selective PDE5 inhibitors developed

Novel potent and selective beta3-adrenergic receptor agonists described

Inflazyme updates shareholders on product development progress

Topical Paclitaxel Gel found safe in two phase I psoriasis trials

LifeTime Pharmaceuticals announces U.S. phase I/II trials of Beta LT for cancer

Hormone replacement therapy shows no cardiovascular benefits in older women

Advanced Tissue Sciences submits PMA for Dermagraft as treatment of diabetic foot ulcers

Allergan in-licenses gatifloxacin from Kyorin for treatment of ocular infections

New compounds interacting with 5-HT1 receptors reported by Pfizer

New compounds under study at Merck useful for dyslipidemias, etc.

Potent, selective muscarinic M3 receptor antagonists patented by Mitsubishi-Tokyo

Actonel approved in Canada

Vitamin D3 derivatives claimed by Teijin for treatment of cystic fibrosis

AMPA/kainate receptor modulators claimed by Egis

V1A/V2 receptor antagonist conivaptan in the news

InKine changes trade name of Diacol to Visicol

Rigel and Novartis establish drug discovery agreement for respiratory therapies

Results of dosing studies on tezosentan in CHF reported

Mast cell tryptase explored as a marker in stable CAD

Vion begins additional phase I trial of intravenous TAPET

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...